# Mitsubishi Tanabe Pharma Corporation

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/mitsubishi-tanabe-pharma-corporation/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | Japanese pharmaceuticals company |
| OpenAlex ID | https://openalex.org/F4320327566 |
| ROR ID | https://ror.org/038ehsm73 |
| Works | 2,459 |

## Funder papers

- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)](https://scholariq.org/papers/double-blind-randomized-placebo-controlled-trial-evaluating-the-efficacy-and/)
- [Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial](https://scholariq.org/papers/effects-of-canagliflozin-on-myocardial-infarction-a-i-post-hoc-i-analysis-of-the/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.